Frangieh, J.; Legendre, C.; Bréard, D.; Richomme, P.; Henrion, D.; Fajloun, Z.; Mattei, C.; Le Ray, A.-M.; Legros, C.
Oxostephanine, Thalmiculine, and Thaliphyline—Three Isoquinoleine Alkaloids That Inhibit L-Type Voltage-Gated Ca2+ Channels. Future Pharmacol. 2022, 2, 238-255.
https://doi.org/10.3390/futurepharmacol2030016
AMA Style
Frangieh J, Legendre C, Bréard D, Richomme P, Henrion D, Fajloun Z, Mattei C, Le Ray A-M, Legros C.
Oxostephanine, Thalmiculine, and Thaliphyline—Three Isoquinoleine Alkaloids That Inhibit L-Type Voltage-Gated Ca2+ Channels. Future Pharmacology. 2022; 2(3):238-255.
https://doi.org/10.3390/futurepharmacol2030016
Chicago/Turabian Style
Frangieh, Jacinthe, Claire Legendre, Dimitri Bréard, Pascal Richomme, Daniel Henrion, Ziad Fajloun, César Mattei, Anne-Marie Le Ray, and Christian Legros.
2022. "Oxostephanine, Thalmiculine, and Thaliphyline—Three Isoquinoleine Alkaloids That Inhibit L-Type Voltage-Gated Ca2+ Channels" Future Pharmacology 2, no. 3: 238-255.
https://doi.org/10.3390/futurepharmacol2030016
APA Style
Frangieh, J., Legendre, C., Bréard, D., Richomme, P., Henrion, D., Fajloun, Z., Mattei, C., Le Ray, A.-M., & Legros, C.
(2022). Oxostephanine, Thalmiculine, and Thaliphyline—Three Isoquinoleine Alkaloids That Inhibit L-Type Voltage-Gated Ca2+ Channels. Future Pharmacology, 2(3), 238-255.
https://doi.org/10.3390/futurepharmacol2030016